Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 3:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 2,298 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Treatment Response Clear all

Conditions: Paget's Disease of Bone
Interventions: Zoledronic Acid, Risedronate, Placebo to Risedronate, Placebo to Zoledronic Acid, Calcium and Vitamin D; Drug · Dietary Supplement
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 30 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 12
States / cities: Santa Monica, California • Lakewood, Colorado • Boca Raton, Florida + 9 more

Conditions: Non-small Cell Lung Cancer
Interventions: cisplatin, Docetaxel, Pegfilgrastim; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Breast Cancer
Interventions: DNA methylation analysis, microarray analysis, polymerase chain reaction, laboratory biomarker analysis; Genetic · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2016
U.S. locations: 4
States / cities: Indianapolis, Indiana • Baltimore, Maryland • Rochester, Minnesota + 1 more

Conditions: Parkinson's Disease
Interventions: Reparative Autologous peripheral nerve tissue; Procedure
Lead sponsor: Craig van Horne, MD, PhD; Other
Eligibility: 45 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast Cancer
Interventions: Trastuzumab (Herceptin), Pertuzumab, Echocardiography, Multigated Acquisition Scan, Mammography, Ultrasound, Magnetic Resonance Imaging, Biospecimen Collection, Questionnaire Administration; Biological · Procedure · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 698
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Jonesboro, Arkansas + 537 more

Conditions: COVID-19, SARS-CoV-2, Inflammatory Bowel Diseases
Interventions: Not listed
Lead sponsor: Connecticut Children's Medical Center; Other
Eligibility: 2 Years to 27 Years
Enrollment: 472 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: HIV Infections
Interventions: Thymopentin; Drug
Lead sponsor: Immunobiology Research Institute; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: San Francisco, California • Tarzana, California • Pittsburgh, Pennsylvania

Conditions: Non-small Cell Lung Cancer, Starting Pemetrexed Based Therapy, Unresectable Cancer
Interventions: Baseline 18F-thymidine (FLT) PET/CT, Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT "flare", Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Asthma
Interventions: fluticasone propionate + montelukast, fluticasone propionate, fluticasone propionate + salmeterol; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 6 Years to 18 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 5
States / cities: Tucson, Arizona • San Diego, California • Denver, Colorado + 2 more

Conditions: Bacteremia
Interventions: Telavancin, Vancomycin, Daptomycin, Synthetic penicillin, Cefazolin; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Psoriasis
Interventions: vehicle foam, calcipotriene, calcipotriene + clobetasol propionate; Drug
Lead sponsor: Leon Kircik, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Head and Neck Cancer
Interventions: cetuximab, cisplatin, TdT-mediated dUTP nick end labeling assay, 3'-deoxy-3'-[18F]fluorothymidine, immunohistochemistry staining method, laboratory biomarker analysis, fludeoxyglucose F 18, radiation therapy; Biological · Drug · Genetic + 2 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hepatocellular Carcinoma
Interventions: 1.0% IP-001 for injection, Surgical Resection and Local Ablation, Local Ablation Alone; Drug · Procedure
Lead sponsor: Robert C. Martin; Other
Eligibility: 18 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Lymphoma, T-Cell, Cutaneous
Interventions: ONTAK (denileukin difitox, DAB389IL-2); Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 9
States / cities: Duarte, California • New Haven, Connecticut • Iowa City, Iowa + 6 more

Conditions: Sepsis, Low Blood Pressure
Interventions: Midodrine, Standard of Care; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 5
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Mankato, Minnesota + 2 more

Conditions: Arthritis, Rheumatoid
Interventions: LY2127399, Placebo; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 19
States / cities: Birmingham, Alabama • Mesa, Arizona • Palm Desert, California + 16 more

Conditions: Kidney Neoplasms
Interventions: IL-2 (interleukin-2), OKT3, Cyclophosphamide, Fludarabine, Mesna; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV-HCV
Interventions: Asunaprevir and Daclatasvir, Asunaprevir and Daclatasvir with BMS-791325; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lung Cancer
Interventions: HP 129Xe MRI; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer, Solid Tumor, Solid Tumor Cancer, Oncology, uPAR-positive Solid Tumor, Urokinase Plasminogen Activator Receptor-positive Solid Tumor
Interventions: MNPR-101-PCTA-177Lu; Biological
Lead sponsor: Monopar Therapeutics; Industry
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Active Systemic Lupus Erythematosus
Interventions: Efavaleukin Alfa, Placebo, Standard of Care; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 51
States / cities: Birmingham, Alabama • Gilbert, Arizona • Glendale, Arizona + 40 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Breath sample collection, Research blood collection; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Response-driven Adaptive Radiation Therapy, Carboplatin, Paclitaxel, FDG-PET, V/Q SPECT, Durvalumab; Radiation · Drug · Device
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Ann Arbor, Michigan

Conditions: Liver Cancer
Interventions: TriNav, Traditional Delivery, Doxorubicin; Device · Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period

Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer

DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer

A Study to Evaluate Feasibility, Safety, and Clinical Responses of Implanting Autologous Peripheral Nerve Tissue Into the Brain for Non-motor or Motor Symptoms in Patients With Parkinson's Disease Undergoing DBS Surgery

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Monitoring Serologic Response to Severe Acute Respiratory Syndrome-2 (SARS-COV-2)/COVID-19 in Children

A Study of Timunox (Thymopentin) in HIV-Infected Patients Receiving Other Anti-HIV Drugs

Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer

Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)

A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial

Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis

3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx

Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone

Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)

MID-STEP (MIDodrine for Sepsis Treatment and Early vasoPressor Weaning) Trial

A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy

Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer

Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV

Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigating Radiation-response and Toxicity

MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer

Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus

Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer

A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer

Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver Malignancies